{"groups":[{"description":"Participants received ipilimumab, 3 mg/kg intravenously (IV), once every 3 weeks (Q3W) for a total of 4 doses (up to approximately 3 months).","id":"FG000","title":"Ipilimumab"},{"description":"Participants received pembrolizumab, 10 mg/kg IV, once every 2 weeks (Q2W) for up to approximately 24 months.","id":"FG001","title":"Pembrolizumab Q2W"},{"description":"Participants received pembrolizumab, 10 mg/kg IV, Q3W for up to approximately 24 months.","id":"FG002","title":"Pembrolizumab Q3W"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"9"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"2"}],"type":"Clinical progression"},{"reasons":[{"groupId":"FG000","numSubjects":"153"},{"groupId":"FG001","numSubjects":"154"},{"groupId":"FG002","numSubjects":"147"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"8"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"}],"type":"Protocol Violation"},{"reasons":[{"groupId":"FG000","numSubjects":"32"},{"groupId":"FG001","numSubjects":"14"},{"groupId":"FG002","numSubjects":"12"}],"type":"Withdrawal by Subject"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"278"},{"groupId":"FG001","numSubjects":"279"},{"groupId":"FG002","numSubjects":"277"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"256"},{"groupId":"FG001","numSubjects":"278"},{"groupId":"FG002","numSubjects":"277"}],"type":"Treated"},{"achievements":[{"groupId":"FG000","numSubjects":"71"},{"groupId":"FG001","numSubjects":"101"},{"groupId":"FG002","numSubjects":"97"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"207"},{"groupId":"FG001","numSubjects":"178"},{"groupId":"FG002","numSubjects":"180"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"834 participants were randomized 1:1:1 to receive ipilimumab Q3W, pembrolizumab Q2W, or pembrolizumab Q3W. For participants receiving pembrolizumab, all safety and efficacy results data reported are for the primary pembrolizumab course received.","recruitmentDetails":"Participants with advanced melanoma were recruited to receive ipilimumab once every 3 weeks (Q3W), or a primary course of pembrolizumab administered every 2 weeks (Q2W) or every 3 weeks (Q3W)."}